Gilteritinib

From WikiMD.org
Jump to navigation Jump to search

Gilteritinib

Gilteritinib (pronounced as gil-te-ri-ti-nib) is a type of medication used in the treatment of acute myeloid leukemia (AML). It is classified as a kinase inhibitor, specifically targeting the FMS-like tyrosine kinase 3 (FLT3) and AXL receptor tyrosine kinase (AXL).

Etymology

The name "Gilteritinib" is derived from the combination of parts of the words "Gilt", "Eri", and "Tinib". "Tinib" is a common suffix for kinase inhibitors. The origin of "Gilt" and "Eri" is not clearly known.

Usage

Gilteritinib is used for the treatment of adults who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. It works by blocking the action of the abnormal protein that signals cancer cells to multiply, helping to slow down or stop the spread of cancer cells.

Related Terms

Side Effects

Common side effects of Gilteritinib include changes in liver function, joint pain, fatigue, fever, and shortness of breath. It can also cause more serious side effects, such as pancreatitis and differentiation syndrome.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski